Akcea Therapeutics, Inc. (NASDAQ:AKCA) Q3 2019 Earnings Conference Call Transcript

Nov 05, 2019 • 04:30 pm ET

Previous

Akcea Therapeutics, Inc. (NASDAQ:AKCA) Q3 2019 Earnings Conference Call Transcript

Share
Close

Loading Event

Loading Transcript

Presentation
Operator
Operator

Good afternoon and welcome to the Akcea Therapeutics Third Quarter 2019 Conference Call. [Operator Instructions]

I will now turn the call over to Kathleen Gallagher Akcea's Vice President of Corporate Communications and Investor Relations. Ms. Gallagher please begin.

Executive
Kathleen Gallagher

Thank you Sade [Phonetics]. Hello everyone. Thank you for joining today's call. With me today are Damien McDevitt our Interim Chief Executive Officer; Mike MacLean our Chief Financial Officer; and Kyle Jenne; our Chief Commercial Officer.

As a reminder this conference call includes forward-looking statements regarding the financial outlook for Akcea Akcea's business and the therapeutic and commercial potential of Akcea's products and development. Any statement describing Akcea's goals expectations financial or other projections intentions or beliefs including the commercial potential of TEGSEDI WAYLIVRA and our pipeline drugs is a forward-looking statement and should be considered an at-risk treatment. Such statements are subject to certain risks and uncertainties particularly those inherent in the process of discovering developing and commercializing drugs that are safe and effective for use as human therapeutics and in the endeavor of building a business around such drugs.

Akcea's forward-looking statements also involve assumptions that if they never materialize or prove correct could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Akcea's forward-looking statements reflect the faith judgment of its management these statements are based only on facts and factors currently known by Akcea.

As a result you're cautioned not to rely on these forward-looking statements. These and other risks concerning Akcea's programs are described in additional detail in Akcea's most recent Quarterly Report on Form 10-Q and in the most recent Annual Report on Form 10-K on file with the SEC. Copies of these and other documents are available from the company. In addition earlier today we issued a press release and related financial tables including a reconciliation of GAAP to our reported non-GAAP financial measures that we will discuss today. To read this release and access the slides that accompany today's call please visit the Investors section of our Web site.

Now I will turn the call over to Damien.

Executive
Damien McDevitt

Thank you Kath. Good afternoon everyone and thank you joining today's call. I want to start off by sharing how excited I am to lead Akcea. I believe in our mission our team and our innovative medicines. Since being appointed interim CEO a little more than a month ago I've worked alongside our dedicated employees and I've heard firsthand the real and positive impact we're having on patient's lives. I have now seen the strong foundation that has been built here and I'm impressed with the talent and engagements across the organization. I've also spent time with our key partners Novartis PTC and now Pfizer and have been impressed with their commitments to our medicines.

Our strategy is to continue to execute on our two commercial launches as well as deliver on the transformational programs that we currently have in developments. I look forward to leveraging this infrastructure as we